Data suggest gene, cell therapy trial initiations in Europe lag behind North America — here's why
Medical science has moved on from the one-size-fits-all approach to the era of personalized medicine. European authorities approved the world’s first-ever gene therapy — GSK’s Strimvelis, a treatment for an inordinately rare inherited disorder characterized by a ravaged immune system, in 2016. So far, the EMA has granted the greatest number of marketing authorizations for advanced therapy medicinal products (ATMPs) —or medicines based on genes, tissues or cells — globally. But data suggest that the number of ATMP clinical trials initiated in Europe has been eclipsed by initiations in North America in recent years.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,000+ biopharma pros reading Endpoints daily — and it's free.